Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
3D MEDICINES二零二三年中期报告
Editas Medicine Inc 2024年度报告
3D MEDICINES-B二零二二年年报
Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines
Annex 1 Socio-Economic Analysis Of the potential restriction of the perand polyfluoroalkyl substances (PFAS) used in the production, packaging and delivery of human medicinal products
Blueprint Medicines Corp 2024年度报告
Disc Medicine Inc美股招股说明书(2025-01-23版)
Disc Medicine Inc美股招股说明书(2025-01-21版)
How Off-Label Use of Medicines Drives Health-Care Use and Disability
公众号
小程序
社群